NCT07919795Not yet recruiting
Beta-2-Trace Protein in Diabetic Nephropathy
Role of Beta-2-Trace Protein as Early Predictor of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
This cross-sectional study aims to evaluate serum beta-2-trace protein levels in patients with diabetic nephropathy compared with healthy controls.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 1 Nov 2026
- Start date
- 10 Nov 2026
- Primary completion date
- 10 Nov 2027
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07919795
What you commit to
- Study type: Observational
- Planned participants: 80
- From 10 Nov 2026 to the primary completion date, 10 Nov 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes mellitus
- Malignancy
- Cardiovascular diseases
Age
- - Age below 18 years
Other
- Acute kidney injury
Who the study is looking for
- - Adult patients aged 18 years or older
- Documented diabetic nephropathy for at least three months (patient group)
- Apparently healthy adults (control group)
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.